DP
Dharmendra Prasad Srivastava
About Dharmendra Prasad Srivastava
Data last updated:
Dharmendra Prasad Srivastava has 7 years in corporate governance. Holds Director role. Currently with 1 company, including Cosmolife Pharmaceuticals Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Cosmolife Pharmaceuticals Private Limited at ₹55,501 (FY 2021).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 02 May 2019 | 2019 | ₹55,501 (FY 2021) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Dharmendra Prasad Srivastava
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dharmendra Prasad Srivastava
Dharmendra Prasad Srivastava has 7 years in corporate governance. Holds Director role. Currently with 1 company, including Cosmolife Pharmaceuticals Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Cosmolife Pharmaceuticals Private Limited at ₹55,501 (FY 2021).
Dharmendra Prasad Srivastava is associated with 1 company as Director, including Cosmolife Pharmaceuticals Private Limited (₹55,501).
Dharmendra Prasad Srivastava has expertise in General Business.
Dharmendra Prasad Srivastava has 7 years in corporate governance.
By reported revenue, the largest current company of Dharmendra Prasad Srivastava is Cosmolife Pharmaceuticals Private Limited, with revenue of ₹55,501 (FY 2021).
Dharmendra Prasad Srivastava currently holds positions at 1 company: Cosmolife Pharmaceuticals Private Limited (₹55,501).